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Abstract
Introduction Co-expression of several receptor tyrosine kinases
(RTKs), including erbB2 and erbB3, is frequently identified in
breast cancers. A member of the RTK family, the kinase-deficient
erbB3 can activate downstream signaling via heterodimer
formation with erbB2. We studied the expression of RTK
receptors in mammary tumors from the wild-type (wt) rat c-neu
transgenic model. We hypothesized that physical and functional
interactions between the wt rat neu/ErbB2  transgene and
mouse  ErbB3-encoded proteins could occur, activating
downstream signaling and promoting mammary oncogenesis.
Methods Immunohistochemical and Western blot analyses
were performed to study the expression of rat c-neu/ErbB2 and
mouse erbB3 in mammary tumors and tumor-derived cell lines
from the wt rat c-neu transgenic mice. Co-immunoprecipitation
methods were employed to quantitate heterodimerization
between the transgene-encoded protein erbB2 and the
endogenous mouse erbB3. Tumor cell growth in response to
growth factors, such as Heregulin (HRG), epidermal growth
factor (EGF), or insulin-like growth factor-1 (IGF-1), was also
studied. Post-HRG stimulation, activation of the RTK
downstream signaling was determined by Western blot
analyses using antibodies against phosphorylated Akt and
mitogen-activated protein kinase (MAPK), respectively. Specific
inhibitors were then used with cell proliferation assays to study
the phosphoinositide-3 kinase (PI-3K)/Akt and MAPK kinase
(MEK)/MAPK pathways as possible mechanisms of HRG-
induced tumor cell proliferation.
Results Mammary tumors and tumor-derived cell lines
frequently exhibited elevated co-expression of erbB2 and
erbB3. The transgene-encoded protein erbB2 formed a stable
heterodimer complex with endogenous mouse erbB3. HRG
stimulation promoted physical and functional erbB2/erbB3
interactions and tumor cell growth, whereas no response to
EGF or IGF-1 was observed. HRG treatment activated both the
Akt and MAPK pathways in a dose- and time-dependent
manner. Both the PI-3K inhibitor LY 294002 and MEK inhibitor
PD 98059 significantly decreased the stimulatory effect of HRG
on tumor cell proliferation.
Conclusion The co-expression of wt rat neu/ErbB2 transgene
and mouse ErbB3, with physical and functional interactions
between these two species of RTK receptors, was
demonstrated. These data strongly suggest a role for erbB3 in
c-neu  (ErbB2)-associated mammary tumorigenesis, as has
been reported in human breast cancers.
Introduction
The erbB or epidermal growth factor receptor (EGFR) family
forms subclass I of the receptor tyrosine kinase (RTK) super-
family. Type I RTKs are expressed by epithelial, mesenchymal
and neural tissues to regulate cell proliferation, differentiation
and other important biological functions critical to species
DMEM = Dulbecco's modified Eagle's medium; EGF = epidermal growth factor; EGFR = EGF receptor; ER = estrogen receptor; FBS = fetal bovine 
serum; HRG = heregulin; IGF-1 = insulin-like growth factor-1; mAb = monoclonal antibody; MAPK = mitogen-activated protein kinase; MEK = MAPK 
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RT-PCR = reverse transcription-polymerase chain reaction; SRB = sulforhodamine B; TCA = trichloroacetic acid; TGF-α  = transforming growth 
factor-α .Breast Cancer Research    Vol 7 No 5    Kim et al.
R709
development [1]. Dysregulated expression of erbB receptors
or mutational events thereof have been implicated in diverse
types of human cancers [1,2]. Members of the family include:
ErbB1 (also known as EGFR), ErbB2 (also known as Her-2 or
neu), ErbB3 (or Her-3) and ErbB4 (or Her-4) [3-7]. erbB2 is
an orphan receptor whereas other family members directly
bind ligands (like the epidermal growth factor (EGF) and trans-
forming growth factor-α  (TGF-α ) for EGFR, and HRG for
erbB3 and erbB4) to initiate intracellular signaling [8].
ErbB2 may be activated via either ligand-dependent het-
erodimeric, or ligand-independent homodimeric processes. In
the former, erbB2 is the preferred heterodimerization partner
for other erbB family receptors with bound ligand [9]. In ligand-
independent signaling, erbB2 may be upregulated as a result
of gene amplification, promoting homodimerization, or be acti-
vated through mutational events. ErbB2  amplification with
enhanced protein expression is noted in approximately one-
third of invasive human breast cancers [10]. Selected het-
erodimers may enhance receptor activation and downstream
signaling as compared with homodimers [1,11,12]. Although
erbB3 lacks a functional kinase to initiate cell signaling
[13,14], the erbB2/erbB3 heterodimer complex is believed to
be the most biologically active and pro-tumorigenic form of
these receptor complexes [15,16].
The erbB receptors and their respective ligands influence a
wide range of cellular processes such as proliferation, matura-
tion, survival, apoptosis and angiogenesis [11,17-19]. In gen-
eral, activated RTKs add phosphorylated tyrosine residues to
downstream signaling molecules, such as the p85 subunit of
phosphatidylinositol 3-kinase (PI-3K), Shc and/or Grb2 of the
mitogen-activated protein kinase (MAPK) pathway. However,
because of the complexity of RTK ligand-dependent and -inde-
pendent mechanisms, the downstream signaling effects may
be highly diverse and interactive. RTK-induced signaling is
also influenced by, and may modulate, other molecular factors
and signaling pathways.
The ErbB2 gene-encoded protein is over-expressed in 25 to
30% of invasive breast and ovarian cancers and has been
associated with a poor clinical outcome [20-25].
Evidence of a causal relationship in human breast cancer has
been derived from numerous prognostic studies and clinical
trials. In vivo and in vitro model systems including transgenic
mouse models support a relationship between erbB2 altera-
tions and mammary tumorigenesis. Overexpression of erbB3
is also frequently reported in erbB2 altered breast, ovarian and
bladder cancers [23,26,27]. Human breast cancer cell lines
commonly co-overexpress both erbB2 and erbB3, further sup-
porting their role in breast carcinogenesis [2,11].
To investigate the role of RTKs in mammary tumorigenesis,
transgenic mice bearing the wild-type (wt) or mutated, acti-
vated rat c-neu  (ErbB2) were generated, and have been
widely studied [28-31]. Transgenic mice expressing the acti-
vated rat c-neu  (with deletion mutations) bear mammary
tumors with elevated co-expression of the mutant c-neu/
ErbB2 and the endogenous mouse ErbB3-encoded protein
[32]. Functional and physical interactions between these two
cross-species receptors have not been reported, although
interactions have been widely speculated. Transgenic mice
bearing the wt-rat c-neu, under control of the mouse mammary
tumor virus promoter (MMTV-LTR), typically develop unifocal,
well-circumscribed, low-grade tumors after a long latency
[29]. In addition to transgene expression and, in some cases,
mutation, upregulation of EGFR and p53 have been reported
in derived tumors [33,34].
We have used the wt-erbB2 transgenic mouse model to study
the effects of exogenous pharmacological or dietary estrogens
and anti-estrogens. In particular, we have studied interactions
between RTK-associated mammary tumorigenesis and steroid
hormones. From the derived mouse tumors, we have estab-
lished over 150 novel murine cell lines which have proven use-
ful for in vitro studies [35,36]. Most tumor-derived cell lines
express significant mouse ErbB3-encoded protein, in addition
to high levels of the rat c-neu/ErbB2 transgene. These are also
typically negative for ERα  but show ERβ  protein expression. A
similar pattern of receptor expression has also been detected
in the mouse mammary tumors.
The co-expression of erbB3 with erbB2 in both the activated
and wt-neu/ErbB2  transgenic model systems suggested a
biological role for erbB3 in mammary tumor pathogenesis. We
hypothesized that physical and functional interactions
between these RTK receptors should occur, despite their
cross-species molecular structures. Signaling initiated by acti-
vated erbB2/erbB3 heterodimers should provide a more
potent oncogenic signal than erbB2 homodimers alone. This
would require ligand binding, most likely HRG, to activate
erbB3. To test this hypothesis, we studied the responsiveness
of tumor-derived cell lines to growth factors, including HRG,
EGF and insulin-like growth factor-1 (IGF-1); we evaluated the
effects of ligand stimulation and heterodimer formation on
downstream signaling activation; and we sought evidence of
physical interactions between the wt-rat c-neu/erbB2 and the
endogenous mouse erbB3.
Materials and methods
Cells and cell culture
Human breast cancer cell lines SKBR-3 and BT-474 were
obtained from the American Type Culture Collection (Rock-
ville, MD, USA) and maintained in DMEM and Ham's F-12
medium (1:1, v/v) (Invitrogen Corp, Grand Island, NY, USA)
supplemented with 10% FBS (Invitrogen Corp). These cell
lines were cultured in a 37°C humidified atmosphere contain-
ing 95% air and 5% CO2 and were split twice a week. These
human breast cancer cells were used primarily as controls.Available online http://breast-cancer-research.com/content/7/5/R708
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Establishment of novel, mouse mammary tumor cell 
lines
Mammary tumors were obtained from the transgenic mice by
surgical removal immediately following euthanasia, according
to our approved IACUC protocol. The histological pattern and
tumor diagnoses were confirmed by microscopic analysis.
These methods have been previously described in detail [35],
although the specific cell lines described in this work have not
been previously published. In brief, solid tumor tissue was
transferred into a tissue culture dish containing PBS. After
removal of mammary fat and connective tissues, tumors were
minced into small pieces and treated with 0.25% trypsin-
EDTA (Invitrogen Corp) at 37°C for 30 min. Cells were subse-
quently centrifuged at 1,200 rpm for 5 min. After discarding
supernatant, cells were suspended in DMEM/F12 medium
supplemented with 10% FBS and 1% antibiotics and antimy-
cotics (Invitrogen Corp). These mammary tumor cells (~1.0 ×
106 cells/plate) were seeded in tissue culture dishes and kept
in a 37°C humidified atmosphere containing 95% air and 5%
CO2. The media was changed twice a week to maintain cells
in culture. Each line was passaged approximately 20 times
before stability was assumed.
Soft agar cloning assays
Soft agar cloning was performed as described previously [35]
with some modification. The bottom agar was prepared with a
mixture of 1.6 ml of 1 × DMEM/F12 (complete medium), 3.2
ml of 2 × DMEM/F12 (complete medium), and 3.2 ml of
1.25% Noble agar (Sigma Co, St Louis, MO, USA) and main-
tained at 42°C. From this, 2 ml was pipetted into each well of
six-well cell culture plates and agar was allowed harden in the
hood. For each well, top agar was a mixture of 0.2 ml of 1 ×
DMEM/F12, 0.4 ml of 2 × DMEM/F12, and 0.4 ml of 0.95%
Noble agar. Five thousand cells (in 80 µl complete medium)
were added into the top agar mixture. After vortexing gently,
the cell containing top agar was added in a drop-wise fashion
onto the bottom agar containing six-well plates (in triplicate per
cell line). After resting for 10 min in the hood, the six-well
plates were cultured in a 37°C incubator for 3 weeks. Colony
counts were obtained under an inverted microscope, from
three wells per cell line counting all colonies >50 µM in
diameter.
Doubling time in culture
Measurement of cell growth rate in culture was determined
using sulforhodamine B (SRB; Sigma Co) assays as previ-
ously described [35]. Two thousand cells were seeded into
each well of a six-well plate with complete medium. Cells were
fixed with 50% trichloroacetic acid (TCA) at 24 h intervals for
3 days. TCA-fixed cells were then stained with 0.4% SRB for
30 min followed by three washes. Protein-bound dye was dis-
solved in 10 mM Tris base. Plates were read at 565 nM using
a micro-plate reader. Cell-doubling time was calculated based
on proliferation curves that resulted from changes in SRB
absorbance over time. Data represent the means of at least
three independent experiments.
Cell proliferation assay
A CellTiter96™ AQ non-radioactive cell proliferation kit
(Promega Corp, Madison, WI, USA) was used to determine
the responsiveness of cells to various growth factors. Cells
were plated onto 96-well plates, 5,000 cells/well for each cell
line. Twenty-four hours later, the culture media were replaced
by 0.5% FBS in DMEM/F12 fresh medium or the same
medium containing 25 ng/ml HRG (R&D Systems, Inc, Minne-
apolis, MN, USA), 10 ng/ml EGF (Sigma Chemical Co), or 40
ng/ml IGF-1 (R&D Systems, Inc) for another 72 h incubation
with 5% CO2 at 37°C. After reading at 490 nM with the micro-
plate reader, the percentages of viable cells were determined
by reduction of MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; inner
salt) relative to controls. Data reflect the means of at least
three independent experiments.
RT-PCR and DNA sequencing analysis
RT-PCR analyses were performed as previously described
[37]. The primers specific for rat neu  were synthesized
according to the literature [38]. Forward primer AB2913, 5'-
CGG AAC CCA CAT CAG GCC-3' and reverse primer
AB1310, 5'-TTT CCT GCA GCA GCC TAC GC-3' amplify
the region corresponding to nucleotides 1492 to 2117 of rat
neu cDNA [38]. The PCR products purified from agarose gel
using QIAquick Gel Extraction Kit (Qiagen, Inc, San Valencia,
CA, USA) were submitted to the core facility at the Oklahoma
Medical Research Foundation for direct sequencing.
Immunohistochemistry
Immunohistochemical staining of mammary tumor tissues was
performed as previously described [39]. Briefly, after depar-
affinization and rehydration, tissue sections were steamed in a
10 mM citrate buffer, pH 6.0, for 30 min. Non-specific reactiv-
ity was blocked with 0.3% H2O2 in buffer. For erbB3 immu-
Table 1
Anchorage-independent cloning of mammary tumor-derived cell lines
Cell Lines SKBR-3a 78423 78617 78717 83923 85815 85819
Colonies in soft agarb 4 2 2 8 74 92 44 11 8 0 1 7
aHuman breast cancer cell line SKBR-3 was used as positive control.
bColony numbers represent average of triplicates for each cell line.Breast Cancer Research    Vol 7 No 5    Kim et al.
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noassays, CAS Block (Zymed Laboratories, Inc, South San
Francisco, CA, USA) and 10% normal horse serum (Vector
Laboratories, Inc, Burlingame, CA, USA) were used sequen-
tially. For phospho-Akt immunostaining, we used 1% H2O2
and 5% normal goat serum (Vector Laboratories, Inc) sequen-
tially. Primary antibodies included an anti-erbB2 (reactive with
rat c-neu/erbB2 rabbit polyclonal, dilution 1:1000 (Dako,
Carpinteria, CA, USA) for 2 h incubation at room temperature),
anti-erbB3 (cross-reacts with mouse and human, mouse mon-
oclonal, dilution 1:50 (NeoMarkers, Inc, Fremont, CA, USA),
overnight incubation at 4°C), anti-phospho-Akt (rabbit polyclo-
nal, diluted in 5% normal goat serum 1:12.5 (Cell Signaling
Technology, Beverly, MA, USA), overnight at 4°C), or anti-
phospho-MAPK (E10 monoclonal antibody, diluted in 5% nor-
mal goat serum 1:25 (Cell Signaling Technology), overnight at
4°C). After multiple washes with buffer, tissue sections were
sequentially incubated for 30 min at room temperature with
diluted biotinylated secondary antibody (1:500; Dako) and
VECTASTAIN Elite ABC reagent (Vector Laboratories, Inc)
diluted in PBS. After reaction with diaminobenzidine (Dako)
and counterstaining with hematoxylin, tumors were individually
examined. Each slide was evaluated in its entirety for antigen
expression, cell type and histopathological diagnoses.
Immunoprecipitation and Western blot analysis
Immunoprecipitation and Western blot assays were per-
formed as previously described [40]. Briefly, cells were lysed
in NP-40 lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl,
0.5% NP-40, 50 mM NaF, 1 mM Na3VO4, 1 mM phenylmeth-
ylsulfonyl fluoride, 25 µg/ml leupeptin, 25 µg/ml aprotinin). The
supernatants were cleared by centrifugation. Protein concen-
trations were measured using the Coomassie plus protein
assay reagent (Pierce Chemical Co, Rockford, IL, USA). Total
cell lysates containing 200 µg of protein were subjected to
immunoprecipitation in the presence of 1 µg anti-erbB2 anti-
body (mouse monoclonal antibody, Ab-4; Oncogene Science
Products, Cambridge, MA, USA) for 2 h at 4°C, followed by
incubation with immobilized protein A-agarose (Roche Diag-
nostics Corp, Indianapolis, IN, USA) at 4°C overnight with
rotation. For Western blot analyses, the immunoprecipitates or
equal amounts of crude extracts were boiled in Laemmli SDS-
sample buffer, resolved by SDS-polyacrylamide gel electro-
phoresis, transferred to nitrocellulose (Bio-Rad Laboratories,
Hercules, CA, USA), and probed with different primary anti-
bodies. After the blots were incubated for another 1 h at room
temperature with horseradish peroxidase-labeled secondary
antibody (goat anti-rabbit IgG or goat anti-mouse IgG; Perkin
Elmer, Boston, MA, USA), the signals were detected using the
Enhanced Chemiluminance assay (Amersham Life Science
Inc., Arlington Heights, IL, USA) according to the manufac-
turer's instructions.
Results
Co-expression of erbB2 and erbB3 protein in tumor-
derived cell lines and tumors
Western blot analyses were used to determine erbB2 and
erbB3 protein expression in tumor-derived cell lines (and the
control SKBR-3 human breast cancer cell line). The majority of
tumor-derived cell lines expressed moderate to high levels of
both erbB3 and erbB2 (Fig. 1). In general, lines with the high-
est erbB2 expression showed the highest levels of erbB3 pro-
tein. Tyrosine phosphorylation (activation) of these receptors
was examined by Western blots using antibodies specific for
phophorylated erbB2 (P-erbB2) or phosphorylated erbB3 (P-
erbB3). Tumor lines with co-overexpression of both proteins
showed higher P-erbB2 and P-erbB3 levels (Fig. 1). The inten-
sity of P-erbB2 and P-erbB3 signals did not necessarily corre-
late with their corresponding protein levels. The expression of
either receptor protein was undetectable in only one of our
novel, derived tumor cell lines (78423). AIB-1 (also called
SRC3, RAC3, ACTR and p/CIP), a co-activator of estrogen
receptor commonly amplified in breast cancer cells [41], was
used as a loading control. Expression of AIB-1 further estab-
lished the origin of these cells as mammary-derived.
To confirm the transformed characteristics of these lines, soft
agar cloning assays (which quantitate anchorage-independent
cloning capability) were used. All six tumor-derived cell lines
formed colonies in soft agar. Colony formation was variable
Figure 1
Protein expression of erbB2, P-erbB2, erbB3, P-erbB3 and AIB1 in  breast tumor cell lines Protein expression of erbB2, P-erbB2, erbB3, P-erbB3 and AIB1 in 
breast tumor cell lines. The cell lysates from human breast cancer cell 
line SKBR-3 and the six novel, mammary tumor-derived cell lines were 
prepared as described in Materials and methods. 50 µg total cell 
lysates were used for Western blot analyses with antibodies directed 
against erbB2 (c-neu Ab-3, Oncogene Research Products), P-erbB2 
(clone PN2A, NeoMarkers, Inc), erbB3 (Ab-7, NeoMarkers, Inc), P-
erbB3 (clone 21D3, Cell Signaling Technology) and AIB1 (clone 34, 
BD Biosciences Pharmingen, San Diego, CA, USA).Available online http://breast-cancer-research.com/content/7/5/R708
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when comparing one cell line with another (range 17–180,
Table 1). There was no correlation between the ability of a cell
line to form anchorage-independent clones and the expression
levels of erbB2 or erbB3.
Immunohistochemical methods were used to visualize RTK
expression and downstream signaling (protein activation) by
tumors in situ. Tumors showed strong and typically diffuse co-
expression of both erbB2 and erbB3. The only exception to
this was the mammary tumor 78423 R1, the progenitor of the
cell line that did not co-express erbB2 and erbB3 discussed
above. We also studied RTK signaling activation in situ, using
phosphospecific antibodies. Phosphorylated-Akt (P-Akt)
showed cytoplasmic and membranous staining, which was
less diffuse than the erbB-2 expression. Phosphorylated-
MAPK (P-MAPK) was the most selectively expressed, typically
expressed by clustered or isolated tumor cells as shown in Fig.
2 (left panel) with tumor 78617 R3. The majority of tumor cells
from 78423 R1 were erbB3 negative, although some cells
showed weak erbB2 protein expression. In this later tumor, P-
Akt staining was weak with clustered or isolated tumor cells
and no staining for P-MAPK was observed (Fig. 2, right panel).
The histological, cytological and biological features of these
tumors have been reported elsewhere [36,42]. As a control,
we also studied cytokeratin expression and all tumors were
positive. This confirmed the epithelial nature of these tumors
(data not shown).
Sequencing analyses of the transgene neu in 
established mammary tumor-derived cell lines
As alluded to above, in-frame deletions of 7–12 amino acids
have been reported in the extracellular region of the transgene,
proximal to the transmembrane domain [38]. To study the
mutational status of tumor-derived lines, we performed RT-
PCR amplification of exactly the same region followed by
direct sequencing analysis. The PCR primers used were spe-
cific for rat neu and were designed to amplify the 603 bp extra-
cellular region [38]. Of six tumor-derived cell lines used in this
manuscript and therefore studied for mutation, only four
showed PCR gene amplification (Fig. 3a). Of these, the
strongest PCR signal was seen in 85819 cells. These data are
consistent with our Western blot results that showed overex-
pression of the rat neu/erbB2 in only the four PCR-positive
lines (Fig. 1). Direct sequencing of the PCR products revealed
no deletion mutations in the amplified product. Sequencing
showed three of the four were wt rat neu cDNA sequence.
Sequencing data from the 83923 cells indicated a mixture of
two kinds of neu cDNA. Using a reverse primer, we verified
that both wt and point mutation neu transcripts co-existed in
83923 cells (Fig. 3b). This suggests biclonal populations or a
heterozygous mutation. Further studies and sub-cloning are in
process.
Mammary tumor cell response to growth factors 
corresponds with erbB receptor data
To study the functionality and interactions of the erbB recep-
tors, 78423 and other three representative mouse mammary
tumor-derived lines with the highest expression of wt erbB2
and co-expression of erbB3 were chosen for further study.
Baseline proliferation was determined using monolayer culture
conditions and the SRB assay (Fig. 4a). Some variability in the
basal doubling time was observed between these cell lines.
The mouse mammary tumor cell lines 78423, 78617, 85815
and 85819 showed population doubling times of 15.15 ±
1.10, 16.25 ± 1.40, 30.85 ± 2.31 and 20.35 ± 1.89 h,
respectively. Using an MTS assay, we then tested the
response of these lines to EGF, HRG and insulin-like growth
factor (IGF)-1 (Fig. 4b). HRG strongly stimulated the prolifera-
tion of three of the four mouse mammary tumor cell lines
(78617, 85815, 85819) with overexpression of both erbB2
and erbB3. Proliferation was not induced by EGF or IGF-1,
which bind to EGFR and IGF-1 receptor, respectively. HRG
also promoted the growth of SKBR-3 and BT-474 human
breast cancer cells (controls). These data strongly support a
functional interaction between the wt-rat neu/ErbB2 and
endogenous mouse erbB3.
Figure 2
Immunohistochemical staining for erbB2, erbB3, phospho-Akt (P-Akt)  and phospho-MAPK (P-MAPK) in mammary tumor tissues Immunohistochemical staining for erbB2, erbB3, phospho-Akt (P-Akt) 
and phospho-MAPK (P-MAPK) in mammary tumor tissues. Representa-
tive photomicrographs were taken from the similar area of 78617 R3 
and 78423 R1 mammary tumor sections (40X).Breast Cancer Research    Vol 7 No 5    Kim et al.
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HRG activation of PI-3K/Akt and MAPK kinase (MEK)/
MAPK signaling promotes mammary tumor cell growth
It is well documented that the MEK/MAPK and PI-3K/Akt path-
ways are the two major signal transduction pathways down-
stream of the erbB receptors [11,17-19]. To determine which
signaling pathways were activated in the mouse-derived mam-
mary tumor cells exposed to HRG, we performed Western
blots to detect P-MAPK or P-Akt. With 2 h of HRG treatment,
both P-Akt and P-MAPK increased in the 85815 and 85819
mouse mammary tumor cell lines (Fig. 5a). This study included
a series of HRG concentrations, and stimulation was maximal
at a concentration of 2.5 ng/ml. Next, we performed a time-
course analysis to further verify these results. HRG stimulated
both Akt and MAPK in 85815 and 85819 cells, whereas it had
no effect on Akt or MAPK activation in the 78423 cells (Fig.
5b). These data were consistent with the results of minimal
stimulation by HRG in this cell line (Fig. 4b). In aggregate,
these data suggest that HRG induces activation of both MEK/
MAPK and PI-3K/Akt signaling transduction pathways in mam-
mary tumor cells with elevated expression levels of both the
transgene rat c-neu/ErbB2  and the endogenous mouse
Figure 3
RT-PCR and sequencing analyses of partial extracellular domain of rat  neu in the tumor-derived cell lines RT-PCR and sequencing analyses of partial extracellular domain of rat 
neu in the tumor-derived cell lines. (a) RT-PCR analyses of rat neu. 
Total RNA isolated from the indicated tumor cells by the TRIZOL rea-
gent was analyzed with electrophoresis using a 1% agarose gel con-
taining ethidium bromide and visualized under UV light (bottom). First-
strand cDNA was synthesized using a kit from Roche Diagnostics 
Corp. The partial extracellular domain of rat neu was amplified with spe-
cific primers. The PCR products were separated on a 1.2% agarose gel 
containing ethidium bromide and visualized under UV light (top). (b) 
Partial sequencing of the PCR product from 83923 cells with reverse 
primer AB1310. The mixture of wt nucleotide T (red) and mutant nucle-
otide A (green) is indicated by an arrow.
Figure 4
Proliferation of the tumor-derived cell lines and their responsiveness to  growth factors Proliferation of the tumor-derived cell lines and their responsiveness to 
growth factors. (a) The tumor-derived cell lines 78423, 78617, 85815 
and 85819 were subjected to SRB assays for measurement of cell 
growth rate as described in Materials and methods. The means of at 
least three independent experiments were plotted. SD for each point 
was less than 10%. (b) The indicated breast cancer cells (5 × 103) in 
0.1 ml culture media were plated onto 96-well plates. After 24 h incu-
bation, cells were grown in either 0.1 ml fresh medium with 0.5% FBS 
as control, or 0.1 ml same medium containing either 25 ng/ml HRG or 
10 ng/ml EGF, and 40 ng/ml IGF-1. Cells were incubated at 37°C with 
5% CO2 for another 72 h, and the percentages of surviving cells from 
each group relative to controls, defined as 100% survival, were deter-
mined by reduction of MTS. Data reflect the means of at least three 
independent experiments.Available online http://breast-cancer-research.com/content/7/5/R708
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ErbB3 gene. This activation was both dose- and time-depend-
ent.
To study cross-species functional interactions between the rat
c-neu/ErbB2 transgene and mouse ErbB3, we evaluated
tumor and tissue expression in vivo, ligand-associated
interactions, and signaling in vitro. Immunohistochemical stud-
ies showed cytoplasmic P-Akt and P-MAPK expression in
tumor cells with erbB2 and erbB3 co-expression,
predominantly a perivascular distribution. In rare tumors with-
out erbB2 and erbB3 expression (e.g. 78423 R1), the perivas-
cular distribution was not identified and only rare cells showed
immunoreactivity. This evidence of perivascular pathway acti-
vation suggests that ligand-associated signaling via erbB3
may be involved. Ligand-associated signaling probably pro-
Figure 5
Effects of HRG on the phosphorylation of Akt and MAPK in tumor- derived cells Effects of HRG on the phosphorylation of Akt and MAPK in tumor-
derived cells. (a) 85815 and 85819 cells were cultured overnight in 
medium containing 0.5% FBS before being exposed to HRG at the 
indicated concentrations for 2 h. Cells were harvested and 50 µg total 
cell lysates were subjected to Western blot analysis for total Akt, phos-
phorylated Akt, total ERK2 (polyclonal antibody C-14; Santa Cruz Bio-
technology, Inc, Santa Cruz, CA, USA), and phosphorylated MAPK 
(E10 mAb; Cell Signaling Technology) expression. β -actin was used as 
loading control. (b) 78423, 85815 and 85819 cells were cultured 
overnight in medium containing 0.5% FBS before being exposed to 2.5 
ng/ml HRG for the indicated time intervals. At each time point, cells 
were harvested and 50 µg total cell lysates were subjected to Western 
blot analysis for total Akt, phosphorylated Akt, total ERK2, and phos-
phorylated MAPK expression. β -actin was used as loading control.
Figure 6
Immunohistochemical staining for phospho-Akt (P-Akt) and phospho- MAPK (P-MAPK) in 78617 R3 and 78423 R1 mammary tumor tissues Immunohistochemical staining for phospho-Akt (P-Akt) and phospho-
MAPK (P-MAPK) in 78617 R3 and 78423 R1 mammary tumor tissues. 
Procedure used was similar to Fig. 2. Representative photomicro-
graphs were taken from perivascular areas of the tumor sections (20X).
Figure 7
Inhibitory effects of PD98059 and LY294002 blocking HRG-mediated  tumor cell proliferation Inhibitory effects of PD98059 and LY294002 blocking HRG-mediated 
tumor cell proliferation. The indicated breast cancer cells (5 × 103) in 
0.1 ml culture media were plated onto 96-well plates. After 24 h incu-
bation, cells were grown in either 0.1 ml fresh medium with 0.5% FBS 
as control, or 0.1 ml same medium containing PD98059 (6.7 µM for 
78617 and 85815, 5 µM for 85819), or LY294002 (3.3 µM for 78617 
and 85815, 2.5 µM for 85819), or 25 ng/ml HRG alone or in combina-
tion of the same concentrations of HRG and PD98059, or HRG and 
LY294002. Cells were incubated at 37°C with 5% CO2 for another 72 
h, and the percentages of surviving cells from each group relative to 
controls, defined as 100% survival, were determined by reduction of 
MTS. Data reflect the means of at least three independent experiments.Breast Cancer Research    Vol 7 No 5    Kim et al.
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vides enhanced growth or pro-tumorigenic signaling, in addi-
tion to ligand-independent, transgene activation. Our data,
and those from others showing frequent erbB3 upregulation in
transgenic mice bearing activated neu/ErbB2, suggest that
the concomitant upregulation of erbB3 and ligand-associated
signaling may be an important additional factor in both wt and
activated  neu/ErbB2-associated mammary tumor develop-
ment. To further define the role of HRG (ligand)-associated
signaling, we utilized derived cell lines and specific inhibitors
in vitro. The PI-3K inhibitor LY294002 was significantly more
potent than the MEK inhibitor PD98059 in blocking the stimu-
latory effects of HRG (Fig. 7). Hence, while the MEK/MAPK
and PI-3K/Akt signaling cascades both contribute HRG
induced proliferation, the PI-3K/Akt pathway appears to pro-
vide the dominant response.
Physical interaction between wt-rat-c-neu/ErbB2 and 
endogenous mouse erbB3
The erbB2/erbB3 complex is believed to be the most biologi-
cally active erbB heterodimer [43,44], with potent activation of
the downstream signaling cascade [13,14]. Since both erbB2
and erbB3 were highly expressed by our mammary tumor cell
lines and HRG-promoted tumor cell proliferation, we sought
physical evidence that the wt-rat-neu/ErbB2 could form a
complex with the endogenous mouse erbB3. Immunoprecipi-
tation of erbB2, followed by Western blot analysis for erbB2
and erbB3 (Fig. 8a) showed a low level of complex formation
between these receptors in untreated cell lines. HRG treat-
ment significantly increased the physical interaction between
the rat transgene and mouse erbB3 in two out of three cell
lines. The antibody we used for immunoprecipitation (c-neu
Ab-4) appeared to be wt-rat-neu/ErbB2-specific, because
human erbB2 was not immunoprecipitated from SKBR-3 cell
lysates (Fig. 8a, upper panel), although it was expressed by
SKBR-3 cells (Fig. 8b, Western blot analysis with c-neu Ab-3).
HRG treatment (for 2 h) did not increase the total protein lev-
els of erbB2 or erbB3 as compared with untreated cell lines
(Fig. 8b).
Discussion
We have shown that transgenic mice bearing the wt-rat c-neu
gene, under control of the MMTV promoter, develop mammary
tumors that overexpress the rat c-neu transgene [45,46] and
the endogenous mouse erbB3 protein, in the vast majority of
cases. We have shown a functional interaction between these
two important RTK receptors and a role for ligand-induced sig-
naling in vitro and in vivo. While others have reported that
transgenic mice bearing activated forms of rat c-neu/erbB2
have co-expression of erbB2 and endogenous erbB3 in mam-
mary tumors [32], direct physical and functional interactions
between these two species receptors have not previously
been reported.
Deletion mutants of the neu oncogene have been reported in
two out of three of the mammary tumors derived from this wt-
rat c-neu transgenic model [38]. We did not find the same
mutation rate or type in selected tumor-derived cell lines. How-
ever, we have identified a potential point mutation in 83923
cells (Fig. 3). This missense mutation is located inside the
same extracellular region of neu where the deletion mutations
have been reported. This particular mutation changes the
amino acid 654 serine (codon AGC) into cysteine (codon
TGC). It is different from the active neu  mutation G664V
reported in the transmembrane domain [47]. The biological
significance of the newly discovered S654C mutant neu is not
yet known.
Using ligand stimulation with or without specific inhibitors, we
have studied RTK-induced signaling in response to HRG and
have shown activation of both PI-3K/Akt and the MEK/MAPK
signal transduction pathways. A greater role for PI-3K/Akt
Figure 8
Increased physical associations between wt-rat c-neu protein and  mouse erbB3 by HRG treatment Increased physical associations between wt-rat c-neu protein and 
mouse erbB3 by HRG treatment. (a) The indicated breast cancer cells 
were cultured overnight in medium containing 0.5% FBS, and then 
incubated with or without 2.5 ng/ml HRG for another 2 h. Cell lysates 
were prepared and 200 µg of total protein was subjected to immuno-
precipitation with anti-erbB2 specific antibody (c-neu Ab-4), followed 
by Western blot analysis for erbB2 (c-neu Ab-3) and erbB3. The bar 
graph underneath was obtained by densitometry analysis. The relative 
signal intensities of erbB3 were measured by EAGLE EYE™ II (Strata-
gene, La Jolla, CA, USA). (b) The same bath of 50 µg total cell lysates 
was subjected to Western blot analysis with antibodies directed 
against erbB2 and erbB3.Available online http://breast-cancer-research.com/content/7/5/R708
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signaling was suggested in response to HRG treatment (Fig.
7). PI-3K/Akt signaling is known to be regulated by erbB2-
mediated tyrosine kinase activity. This pathway plays a crucial
role in cell proliferation and survival [18] and has been associ-
ated with the pathogenesis of human breast cancers. PI-3K/
Akt activation has also been cited as a key pathway that
influences chemo-resistance patterns [48,49]. Akt is fre-
quently upregulated in ErbB2  amplified or overexpressing
human breast cancer cells. These similarities between our
transgenic model and human breast carcinogenesis suggest
that the model and derived tumor cell lines may be a useful
resource to study ligand dependent and independent RTK sig-
naling in vivo and in vitro.
As a major ligand for erbB3, HRG is known to bind to erbB3,
foster heterodimer complex formation and promote potent
downstream signaling [12]. HRG can thus promote mammary
tumorigenesis, cell growth, differentiation and phenotypic
aggression [50]. Our immunohistochemical studies of tumors
for phosphorylated proteins facilitated studies of the cellular
location and architectural context of signaling. We noted
enhanced phosphorylated Akt and MAPK in a perivascular dis-
tribution in mammary tumors, with overexpression of both
erbB2 and erbB3 (Fig. 6), suggesting that circulating HRG
may enhance the physical and functional erbB2/erbB3 inter-
actions in vivo, similar to what we observe in vitro. This study
has focused primarily on erbB3, whereas others have demon-
strated upregulation of EGFR in tumors (by immunohisto-
chemistry and Western blot) in the same model system [33].
Low and variable expression of EGFR has also been found in
mammary tumors that develop in transgenic mice bearing acti-
vated forms of rat c-neu/ErbB2 [32]. Using in vitro analyses of
the tumor-derived cell lines, we have found no significant phys-
ical or functional interaction between EGFR (erbB1) and
erbB2 in the presence of EGF (data not shown). However, by
immunohistochemical study, we also detected erbB1 expres-
sion at the tumor periphery as reported by DiGiovanna [33].
These data suggest to us that erbB3 plays a more significant
role in tumorigenesis than erbB1 in this model system.
These data and this model probably have relevance to human
breast cancer biology and treatment strategies. We have
reported that only a minority of erbB2-altered invasive human
breast cancers have overexpression of erbB1 (EGFR) and
activation of erbB2 [51]. Given the complexity of the RTK
receptors, various ligands and downstream signaling, it is likely
that combinations of these factors including erbB3 contribute
to cell signaling, biological behavior and treatment response
[52,53]. To date, the role of erbB3 in human breast carcino-
genesis is not well defined, although many investigators have
suggested that HRG-associated signaling may be important.
In view of these complexities, it is not surprising that erbB2
aberrant breast cancers have shown variable responses to
anti-erbB2 therapeutics [52,53]. It is widely believed that co-
expression of other erbB RTK family members may be one
mechanism of Herceptin resistance [54]. Ligand-induced het-
erodimerization between erbB3 and erbB2, the most potent
signaling complex amongst the various heterodimers, is one
likely mechanism of Herceptin resistance [55]. More detailed
investigations using banks of human tumors and clinical trial-
associated specimens, to define the incidence of erbB3
abnormalities, functional complex formation and downstream
signaling, may provide important new clues regarding these
interactions and their role in breast carcinogenesis.
Conclusion
Our results indicate that over-expression of endogenous
mouse erbB3 plays an important role in the development and
progression of mammary tumors that arise in mice bearing the
wt-rat c-neu transgene. The functional and physical interac-
tions between these important cross-species erbB receptors
result in activation of both PI-3K/Akt and MEK/MAPK signal-
ing. These data support the concept that ligand-dependent
and -independent signaling through erbB2 may promote mam-
mary tumorigenesis in these transgenic mice, similar to what is
observed in human breast cancers.
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